Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine in advanced GI and lung cancer
NCT06338683Phase 3Recruiting
- Sponsor
- Qinghai Red Cross Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in gastric cancer (GC), esophageal cancer, hepatopancreaticobiliary cancers (HPB), lung cancer, sponsored by Qinghai Red Cross Hospital. Started Mar 2024; status: recruiting.
02
Drugs
olanzapine
03
Conditions
gastric cancer (GC)esophageal cancerhepatopancreaticobiliary cancers (HPB)lung cancer
Beyond the preview
Go deeper on NCT06338683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06338683.